Pediatrix Medical Group, Inc. (NYSE:MD) CEO Sells $119,769.00 in Stock

Pediatrix Medical Group, Inc. (NYSE:MD) CEO James D. Swift sold 11,100 shares of Pediatrix Medical Group stock in a transaction on Friday, August 30th. The stock was sold at an average price of $10.79, for a total value of $119,769.00. Following the sale, the chief executive officer now directly owns 170,001 shares of the company’s stock, valued at approximately $1,834,310.79. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Pediatrix Medical Group Price Performance

Pediatrix Medical Group stock opened at $10.74 on Friday. The stock has a fifty day moving average of $8.91 and a 200-day moving average of $8.68. The stock has a market capitalization of $922.24 million, a P/E ratio of -12.64, a price-to-earnings-growth ratio of 1.70 and a beta of 1.56. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.38 and a current ratio of 1.38. Pediatrix Medical Group, Inc. has a 52 week low of $6.62 and a 52 week high of $13.31.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.31 by $0.03. Pediatrix Medical Group had a negative net margin of 12.58% and a positive return on equity of 10.59%. The company had revenue of $504.30 million during the quarter, compared to the consensus estimate of $505.49 million. During the same quarter last year, the firm posted $0.37 EPS. The company’s quarterly revenue was up .7% on a year-over-year basis. On average, sell-side analysts expect that Pediatrix Medical Group, Inc. will post 1.18 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on MD. UBS Group lifted their price objective on shares of Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a “neutral” rating in a research note on Friday, August 9th. Deutsche Bank Aktiengesellschaft raised Pediatrix Medical Group from a “sell” rating to a “hold” rating and set a $8.00 price target on the stock in a research report on Friday, June 7th. Truist Financial lifted their price objective on Pediatrix Medical Group from $8.00 to $10.00 and gave the company a “hold” rating in a report on Thursday, August 15th. Finally, StockNews.com upgraded Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research report on Wednesday, August 7th. Six analysts have rated the stock with a hold rating, According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $9.30.

Institutional Investors Weigh In On Pediatrix Medical Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Boston Partners bought a new stake in Pediatrix Medical Group in the 4th quarter valued at about $12,452,000. Clark Estates Inc. NY purchased a new position in Pediatrix Medical Group during the 4th quarter valued at about $3,302,000. Connable Office Inc. purchased a new position in Pediatrix Medical Group during the 4th quarter valued at about $217,000. Charles Schwab Investment Management Inc. grew its holdings in Pediatrix Medical Group by 10.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,634,065 shares of the company’s stock valued at $15,197,000 after buying an additional 148,600 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in Pediatrix Medical Group by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 10,557,572 shares of the company’s stock valued at $105,892,000 after buying an additional 164,333 shares in the last quarter. 97.71% of the stock is currently owned by institutional investors.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.